Aernoud Fiolet

227 Colchicine in chronic coronary disease in relation to history of acute coronary syndrome Funding: This trial was supported by the National Health Medical Research Council of Australia, a grant from the Sir Charles Gairdner Research Advisory Committee, the Withering Foundation the Netherlands, the Netherlands Heart Foundation, the Netherlands Organization for Health Research and Development, and a consortium of Teva, Disphar, and Tiofarma in the Netherlands. The funders did not have any role in the design or conduct of the study, in the collection, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript. Disclosures: AM reports grants from Novartis, and personal fees from Amarin, Amgen, BMS, Boehringer Ingelheim, MSD, Pfizer. JWE reports consulting/honoraria support from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi- Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis, Servier and grants and/or in-kind support from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis. PLT reports grants, travel support and honoraria from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer. JHC reports membership of advisory boards with Amgen, AstraZeneca. TSJO, ATLF, AvM, SMN, MD, JWMvE, EAvB, FdH, CB, WAB, JGPT and SEM have nothing to disclose. Acknowledgements: We thankall thepatients for theirparticipation in the trial; the trial investigators and coordinators at all the centers; and the trial monitors and staff from GenesisCare, including Penny Buczec, Denny Craig, Karen Doherty, Louise Ferguson, Louise Nidorf, and Karen Youl, from the Heart and Vascular Research Institute of Sir Charles Gairdner Hospital, including Louise Ferguson, and from the Dutch Network for Cardiovascular Research, including Marjelle van Leeuwen (project manager), Ingrid Groenenberg and Glentino Rodriguez for data management, Erik Stroes, Max Silvis, and Tim de Vries for medical review, and Petra Bunschoten and Wendy Tousain for site monitoring.